|Publication number||US3071509 A|
|Publication date||Jan 1, 1963|
|Filing date||Mar 9, 1961|
|Priority date||Mar 9, 1961|
|Publication number||US 3071509 A, US 3071509A, US-A-3071509, US3071509 A, US3071509A|
|Inventors||Robert C O'neill|
|Original Assignee||Stauffer Chemical Co|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (1), Referenced by (26), Classifications (6)|
|External Links: USPTO, USPTO Assignment, Espacenet|
United States Patent Ofifice Patented Jan. 1, 1963 3,071,509 N-Atkrt-Noarstcornsnuutcornsn ANrAooNisr No Drawing. Filed Mar. 9, 1961, Ser. No. 94,446 4 flaims. (Cl. 167-55) The present invention is concerned with certain novel pharmaceutical dosage forms. In particular, it is concerned with unitary dosage forms of certain compounds which I have found exert a physiological response antagonistic to that of nicotine.
The present application is a continuation in part of my copending application Serial Number 3,718, filed on January 21, 1960, noW Patent No. 2,981,641.
Many persons who smoke tobacco desire to break the smoking habit, or at least to diminish the amount of smoking. The reasons for such desire are many and varied, any may be based on advice from a physician or purely on economic considerations. in any case, it has been the experience of numerous smokers, and particularly of very heavy smokers, that it is very difficult to give up the tobacco habit. There are also many persons upon whom the nicotine absorbed from smoked tobacco exerts an undesired effect, for example, upon blood pressure or gastric secretion.
The present invention provides a help to the solution of the above problems. According to the present invention, the smoker orally ingests a unitary dosage form of a nicotine antagonist.
The nicotine antagonists useful in the present invention are compounds which are chemically related to nicotine itself, but they differ from nicotine in that the methyl group present on the nitrogen atom in the 5- membered ring of nicotine has been replaced by a lower alkyl group containing from 2 to 8 carbon atoms. The compounds are, chemically, N-alkyl nornicotines. As examples of suitable alkyl groups, there may be mentioned ethyl, propyl, isopropyl, hexyl, isobutyl, octyl, and, preferably, allyl, which is an unsaturated alkyl group.
The antagonist may be used in the form of thefree base, but it is preferred to use it in the form of an acid addition salt. The salt may be of any non-toxic acid, for example, citric acid, m-alic acid, acetic acid, hydrochloric acid, sulfuric acid, phosphoric acid, and the like.
When taken by the smoker, the nicotine antagonists of the present invention diminish the physiological responses elicited in the smoker by nicotine and the related alkaloids absorbed from the smoke.
On the average, about 3 to 4 mgm. of nicotine are absorbed from the puffed smoke of an average cigarette. The smoke of a 10 gram cigar may contain some to more than 40 mgm. of nicotine. (See Goodman and Gilman, The Pharmacological Basis of Therapeutics, 2nd Edition, 1956, p. 624.) The dosage of the antagonist should be of approximately the same order of magnitude as the amount of nicotine absorbed by the smoker. For the majority of smokers, the daily dosage will be from about 5 mgm. to about 250 mgrn. Particularly in the case of dosages toward the upper end of this range, the antagonist is preferably taken in split dosages, say three or four a day. Most desirably, the dosage is taken in the form of a sustained release capsule or tablet.
The unitary dosage forms of the present invention may be formulated in accordance with conventional practices well-known in the art. Any compatible inert excipient may be used. Examples include starch, milk sugar, calcium phosphate and the like. The preparation of sustained release dosage forms is also a well developed art, and such forms of the antagonist may be prepared in accordance With Well-known methods.
Example I Fifty mgm. of the citrate salt of N-alkyl nornicotine is mixed with 200 mgm. of starch, and the mixture is pressed into a tablet. One such tablet is taken at each of 3 meals daily by a smoker who averages forty cigarettes a day. The usual physiological responses due to smoking are diminished, and the craving for tobacco is decreased.
The foregoing example is given solely for the purposes of illustration and is not to be construed as limitation of the invention, many variations of which will occur to those skilled in the art Without departing from the spirit or scope thereof.
What is claimed is:
1. A unitary dosage form suitable for oral ingestion comprising from about 5 to about 250 mgm. of a compound selected from the group consisting of N-alkyl nornico-tine compounds containing from 2 to 8 carbon atoms in the alkyl group, and addition salts thereof with non-toxic acids, together with a carrier.
2. A sustained release unitary dosage form suitable for oral ingestion comprising from about 5 to about 250 mgm. of a compound selected from the group consisting of N-alkyl nornicotine compounds containing from 2. to 8 carbon atoms in the alkyl group, and addition salts thereof with non-toxic acids.
3. A unitary dosage form suitable for oral ingestion, comprising from about 5 to about 250 mgm. of the citrate of N-allyl nornicotine together with a carrier.
4. A sustained release unitary dosage form suitable for oral ingestion comprising from about 5 to about 250 mgm. of the citrate of N-allyl nornico-tine.
References Cited in the file of this patent UNITED STATES PATENTS 2,981,641 ONeill Apr. 25, 1961
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US2981641 *||Jan 21, 1960||Apr 25, 1961||Stauffer Chemical Co||Tobacco products|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US4574151 *||Aug 11, 1983||Mar 4, 1986||Peter Robin Broughton Lawrence||Amine salts and products containing them|
|US4806356 *||Apr 3, 1987||Feb 21, 1989||Shaw Alec S W||Tobacco product|
|US5122366 *||Sep 25, 1989||Jun 16, 1992||The Arab Pharmaceutical Company||Antismoke mouth wash comprising silver nitrate and propylene glycol|
|US5316759 *||Mar 23, 1992||May 31, 1994||Robert J. Schaap||Agonist-antagonist combination to reduce the use of nicotine and other drugs|
|US5574052 *||Apr 29, 1994||Nov 12, 1996||Robert J. Schaap||Agonist-antagonist combination to reduce the use of nicotine and other drugs|
|US5935975 *||Apr 30, 1993||Aug 10, 1999||Robert J. Schaap||Agonist-antagonist combination to reduce the use of nicotine and other drugs|
|US7682633||Mar 6, 2009||Mar 23, 2010||Alpharma Pharmaceuticals, Llc||Pharmaceutical composition|
|US7682634||Mar 23, 2010||Alpharma Pharmaceuticals, Llc||Pharmaceutical compositions|
|US8039459||Jul 15, 2005||Oct 18, 2011||Universite Laval||Nicotinic receptor agonists for the treatment of inflammatory diseases|
|US8158156||Jun 19, 2007||Apr 17, 2012||Alpharma Pharmaceuticals, Llc||Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist|
|US8551983||Jul 8, 2011||Oct 8, 2013||Universite Laval||Nicotinic receptor agonists for the treatment of inflammatory diseases|
|US8557804||Jul 26, 2011||Oct 15, 2013||Universite Laval||Nicotinic receptor agonists for the treatment of inflammatory diseases|
|US8623418||Dec 16, 2008||Jan 7, 2014||Alpharma Pharmaceuticals Llc||Pharmaceutical composition|
|US8685443||Apr 23, 2010||Apr 1, 2014||Alpharma Pharmaceuticals Llc||Sequestering subunit and related compositions and methods|
|US8685444||Apr 23, 2010||Apr 1, 2014||Alpharma Pharmaceuticals Llc||Sequestering subunit and related compositions and methods|
|US8846104||Feb 13, 2012||Sep 30, 2014||Alpharma Pharmaceuticals Llc||Pharmaceutical compositions for the deterrence and/or prevention of abuse|
|US8877247||Feb 22, 2010||Nov 4, 2014||Alpharma Pharmaceuticals Llc||Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist|
|US20080221085 *||Jul 15, 2005||Sep 11, 2008||Universite Laval||Nicotinic Receptor Agonists for the Treatment of Inflammatory Diseases|
|US20080233197 *||Jun 19, 2007||Sep 25, 2008||Francis Joseph Matthews||Pharmaceutical compositions|
|US20090162450 *||Mar 6, 2009||Jun 25, 2009||Alpharma Pharmaceuticals, Llc.||Pharmaceutical composition|
|US20100143483 *||Feb 22, 2010||Jun 10, 2010||Alpharma Pharmaceuticals, Llc.||Pharmaceutical compositions|
|US20100151014 *||Dec 16, 2008||Jun 17, 2010||Alpharma Pharmaceuticals, Llc||Pharmaceutical composition|
|US20100152221 *||Dec 16, 2008||Jun 17, 2010||Alpharma Pharmaceuticals, Llc||Pharmaceutical composition|
|US20100266645 *||Dec 16, 2008||Oct 21, 2010||Alfred Liang||Pharmaceutical compositions|
|US20110014280 *||Jan 20, 2011||Garth Boehm||Sequestering subunit and related compositions and methods|
|US20110027455 *||Apr 23, 2010||Feb 3, 2011||Garth Boehm||Sequestering subunit and related compositions and methods|
|U.S. Classification||514/343, 131/270, 546/276.4|